

## INDEX TO VOLUME 11

### SUBJECT INDEX

- Abortifacient and luteolytic effects of silicone vaginal rings containing 15 (S) 15-methyl PGF<sub>2α</sub> methyl ester (monkey), 409
- Abortifacient effect in early gestation, oxymetholone, 669
- Abortion,
  - early second trimester, extra-amniotic instillation of rivanol solution and single prostaglandin F<sub>2α</sub> dose, 523
  - intramuscular (15S)-15 methyl prostaglandin F<sub>2α</sub>, 279
  - midterm, induction with Silastic-PVP tubes containing prostaglandins E<sub>2</sub> and F<sub>2α</sub> (rabbit, hamster), 479
  - midtrimester, intramuscular injection of 15-methyl prostaglandin F<sub>2α</sub>, 533
- Acceptability, evaluation by contraceptive method, 363
- Adrenergic agonists and chemical sympathectomy, effect on fertility (mouse), 563
- Agonists, adrenergic, effect on fertility (mouse), 563
- Amenorrhea, post-pill, utilization of Lippes loop, 85
- Amenorrhoea after oral contraceptives, treatment and follow-up, 123
- Androgen with antigonadotropic steroid, effect on male fertility, rat, (91)
- Antigonadotropic steroid plus replacement androgen, effect on male fertility (rat), 91
- Assessment of clinical testing methodology, 363
- Basal body temperature,
  - effect of hypophyseal stimulation by LH-RH, 271
  - d-norgestrel as a postcoital contraceptive agent, 31
- Biochemical changes in Fallopian tube and uterus,
  - effect of Centchroman (monkey), 309
  - effect of DBF (monkey), 317
  - influence of ethynodiol diacetate (monkey), 297
  - influence of megestrol acetate (monkey), 297
  - influence of norethynodrel (monkey), 297
  - influence of progestational contraceptive agents (monkey), 297
- Biochemical changes in spermatozoa and luminal contents, different regions of epididymis (monkey), 689
- Biochemical study, once-a-month contraceptive pill, quinestrol-quinestanol acetate, 681
- Biochemistry, Leydig cells, fundamental advances, 571
- Biological actions of endouterine copper, 209
- Blastocyst surface charge and implantation (mouse), 441
- Bleeding patterns, measurement of effect by contraceptive method, evaluation, 363

## CONTRACEPTION

- Centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-p-( $\beta$ -pyrrolidino-ethoxy)-phenyl-7-methoxy chroman)
- Centchroman, effect on biochemistry of Fallopian tube and uterus (monkey), 309
- Cervical function, d-norgestrel as a postcoital contraceptive agent, 31
- Cervical mucus,
  - influence of copper IUD and lippes loop on sperm migration, 541
  - levels of peroxidase during menstrual cycle, 677
- Chemical sympathectomy and adrenergic agonists, effect on fertility (mouse), 563
- $\alpha$ -Chlorohydrin (3-chloro-1,2-propanediol)
- $\alpha$ -Chlorohydrin,
  - effect on cauda epididymis (rat), 69
  - effect on general physiological status (rat), 69
  - effect on spermatozoa (rat), 69
- 6-Chloro-9 $\beta$ , 10 $\alpha$ -pregna-1,4,6-triene-3,20-dione (Ro 4-8347)
- 3-Chloro-1,2-propanediol ( $\alpha$ -Chlorohydrin)
- Clinical studies,
  - communication of results, 363
  - protocols, role of research design, 363
- Clinical testing methodology,
  - assessment, 363
  - evaluation of data analysis procedures, 363
  - evaluation of role of research design, 363
  - specific problems in contraceptive method evaluation, 363
- Comparison between methods, role of research design, 363
- Comparison between physicians vs. paramedics, role of research design, 363
- Complication associated with a forgotten IUD, 637
- Condom, spermicidally lubricated, use-effectiveness, 701
- Confidence limits, evaluation of data analysis procedures, 363
- Copper, endouterine, biological effects, 209
- Copper IUCD, effect of estradiol and progesterone uptake in uterus (rat), 45
- Copper IUD,
  - biological effects,
    - endometrial changes, 209
    - endometrial enzymes, 209
    - immunological mechanisms, 209
    - implantation and embryogenesis, 209
    - ovulation and fertilization, 209
    - protein and nucleic acid synthesis, 209
    - sperm, 209
    - subsequent fertility, 209
    - uterine fluid enzymes, 209
    - uterine motility, 209
  - corrosion and its fate, 209
- Copper IUD and Lippes loop, influence on sperm migration in cervical mucus, 541

- Copper-7, compared to TCu-200, safety and effectiveness, 243
- Copper-T IUD,
  - safety and effectiveness, 243
  - subcellular distribution of trace metals in secretory endometrium, 451
- Copper-T-200, early puerperal insertions, 289
- Copper wire, intrauterine, effect on resorption of fetuses (rat), 79
- Corpus luteum function, effect of continuous oral administration of estriol, 427
- CuT-200, early puerperal insertions, 289
- Dalkon Shield,
  - compared to TCu-200, safety and effectiveness, 243
  - event rates in nulligravid and nulliparous women, 61
  - Latin American study, 711
  - morphological studies of tails, 465
  - net cumulative event rates, United Kingdom trial, 1
  - United Kingdom trial, 1
  - use-effectiveness, four Latin American countries, 711
- Dalkon Shield vs. Lippes loop D, net cumulative rate, international comparison, 711
- DBF (2-phenyl-3-p-( $\beta$ -pyrrolidinoethoxy)-phenyl-6-methoxy benzofuran hydrochloride
- DBF, effect on biochemistry of Fallopian tube and uterus (monkey), 317
- Dehydroepiandrosterone, level in endometrium, 169
- Dihydrotestosterone, plasma, effect of male contraceptive agent, norethandrolone and testosterone, 193
- EACA (epsilon aminocaproic acid)
- EACA,
  - intrauterine medication with IUD (monkey), 395
  - medication with IUD, quantitation of menstrual blood loss (monkey), 395
- Early puerperal insertions, copper-T-200, 289
- Effectiveness and safety of IUD, 243
- Endocrine responses to vasectomy, long-term (rat), 143
- Endometrium,
  - level of dehydroepiandrosterone, 169
  - level of estradiol, 169
  - level of estrone, 169
  - level of pregnenolone, 169
  - level of progesterone, 169
  - level of testosterone, 169
  - levels of unconjugated steroids, 169
  - secretory, subcellular distribution of trace metals with copper-T IUD, 451
- Endouterine copper, biological actions, 209
- Epididymal tubule, cauda, effect of  $\alpha$ -chlorohydrin (rat), 69
- Epididymis, different regions, biochemical changes in spermatozoa and luminal contents (monkey), 689

## CONTRACEPTION

- Epsilon aminocaproic acid (EACA)
- Estradiol,
  - level in endometrium, 169
  - plasma, effect of intrauterine progesterone, 179
  - plasma level,
    - effect of continuous oral administration of estriol, 427
    - after I.M. injection of norethindrone enanthate, 419
  - serum level,
    - d-norgestrel as a postcoital contraceptive agent, 31
    - termination of early gestation with intramuscular (15S)-15 methyl prostaglandin  $F_{2\alpha}$ , 279
    - termination of early gestation with  $\delta$ -methylolone, 669
- Estradiol and progesterone uptake in uterus, effect of IUCD (rat), 45
- Estriol,
  - conjugated and unconjugated, plasma levels, effect of continuous oral administration of estriol, 427
  - continuous oral administration, effect on corpus luteum function, 427
- Estrone, level in endometrium, 169
- 17 $\alpha$ -Ethynyl- $\Delta^4$ -estrone-17 $\beta$ -ol-one-17 $\beta$  enanthate (norethindrone enanthate)
- Ethynyl estradiol and norethindrone, low dose, effects on serum gonadotropins and progesterone, 329
- 13-Ethyl-17 $\alpha$ -ethynyl-17 hydroxygona-4,9,11-trien-3-one (R-2323)
- 17 $\alpha$ -Ethyl-17-hydroxy-19-nor-4-androsten-3-one (norethandrolone)
- Ethynodiol diacetate, biochemical changes in Fallopian tube and uterus (monkey), 297
- Event rates,
  - classification, evaluation of data analysis procedures, 363
  - comparison in nulligravid and nulliparous women, Dalkon Shield, 61
  - evaluation of data analysis procedures, 363
- Extra-amniotic instillation of rivanol solution and single prostaglandin  $F_{2\alpha}$  dose, early second trimester abortion, 523
- Failures, patient and methods, evaluation of data analysis procedures, 363
- Fallopian tube and uterus, biochemical
  - changes with progestational contraceptive steroids (monkey), 297
  - effect of Centchroman (monkey), 309
  - effect of DBF (monkey), 317
- Family planning acceptance, postpartum, influence of institutional and convenience factors, 133
- Family planning service, collecting information, 651
- Fertility, recovery after discontinuation of contraceptive
  - method, evaluation, 363
- Fertility control, relevance of Leydig cells, 571
- Fetuses, resorption, effect of intrauterine copper wire (rat), 79

- Follicle stimulating hormone, plasma,
  - effect of intrauterine progesterone, 179
  - effect of male contraceptive agent, norethandrolone and testosterone, 193
- Follicle stimulating hormone, serum levels, effect of low dose
  - norethindrone and ethinyl estradiol, 329
- Follow-up of subjects, role of research design, 363
- Forgotten IUD, associated complication, 637
- Function, Leydig cells, biological significance, 571
- Gonadotropins and progesterone, serum levels, effect of low dose
  - norethindrone and ethinyl estradiol, 329
- HCG, serum level, termination of early gestation with
  - intramuscular (15S)-15 methyl prostaglandin  $F_{2\alpha}$ , 279
  - oxymetholone, 669
- Heat in male contraception,
  - hot water 60°C (rat) 549
  - infrared (rat), 549
  - microwave (rat), 549
  - ultrasound (rat), 549
- Hormonal contraceptives, influence on sex hormone binding
  - globulin (SHBG), 53
- Hospital family planning service, collecting information, 651
- Hot water 60°C, use in male contraception (rat), 549
- 17 $\beta$ -Hydroxy-2-(hydroxymethylene)-17-methyl-androstan-3-one
  - (oxymetholone)
- 17 $\alpha$ -Hydroxyprogesterone, serum level, termination of early gestation
  - with intramuscular (15S)-15-methyl prostaglandin  $F_{2\alpha}$ , 279
- Hypophyseal stimulation by LH-RH, effect on ovulatory cycle, 271
- Hypothalamic-hypophyseal-ovarian axis, effect of intrauterine
  - progesterone, 179
- Hysteroscopic tubal fulguration for sterilization, critical
  - appraisal, 261
- Hysteroscopy for localization and removal of IUCD with "missing
  - strings", 161
- Implantation and blastocyst surface charge (mouse), 441
- Implants,
  - Silastic, containing R-2323, 625
  - steroid-releasing, long-term contraception with norethindrone acetate, 505
- Information collection, hospital family planning service, 651
- Infrared, use in male contraception (rat), 549
- Intramuscular medroxyprogesterone acetate, three-monthly in-
  - jections, 15
- Intrauterine
  - copper wire, effect on resorption of fetuses (rat), 79
  - devices, safety and effectiveness, 243
  - progesterone, effect on hypothalamic-hypophyseal-ovarian axis, 179
- IUCD,
  - effect of estradiol and progesterone uptake in uterus (rat), 45
  - hysteroscopy for localization and removal, 161

## CONTRACEPTION

- IUD,
  - complication associated with forgotten device, 637
  - continuous release of progesterone, 179
  - copper, biological effects, 209
  - copper IUD and Lippes loop, influence on sperm migration in cervical mucus, 541
  - copper wire, effect on resorption of fetuses (rat), 79
  - copper-T, subcellular distribution of trace metals in secretory endometrium, 451
  - Dalkon Shield
    - Latin American study, 711
    - morphological studies of tails, 465
    - nulligravid and nulliparous, 61
    - United Kingdom trial, 1
  - medication with EACA (monkey), 395
  - safety and effectiveness, 243
  - utilization of Lippes loop for post-pill amenorrhea, 85
- Leydig cell,
  - biochemistry, fundamental advances, 571
  - biology
    - significant development, review, 571
    - unsolved problems, 571
  - function, biological significance, 571
  - morphology, fundamental advances, 571
  - physiology, fundamental advances, 571
- Leydig cells,
  - relevance to fertility control, 571
  - review, 571
- LH-RH hypophyseal stimulation, effect on ovulatory cycle, 271
- Lipids, serum level, quinestrol-quinestanol acetate, once-a-month, 681
- Lippes loop,
  - influence on sperm migration in cervical mucus, 541
  - utilization in post-pill amenorrhea, 85
  - D vs. Dalkon Shield, net cumulative rate, international comparison, 711
- Liver function studies, quinestrol-quinestanol acetate, once-a-month, 681
- Long-term contraception with steroid-releasing implants, norethindrone acetate, 505
- Loop D, compared to TCU-200, safety and effectiveness, 243
- Luminal contents and spermatozoa, biochemical changes in different regions of epididymis (monkey), 689
- Luteinizing hormone,
  - plasma,
    - effect of intrauterine progesterone, 179
    - effect of male contraceptive agent, norethandrolone and testosterone, 193
  - plasma level,
    - effect of continuous oral administration of estriol, 427
    - effect of hypophyseal stimulation by LH-RH, 271
  - serum levels,
    - norethindrone and ethinyl estradiol, 329
    - d-norgestrel as a postcoital contraceptive agent, 31

- Luteolytic and abortifacient effects of silicone vaginal rings containing 15(S) 15-methyl PGF<sub>2α</sub> methyl ester (monkey), 409
- Male antifertility, antigonadotropic steroid plus replacement androgen (rat), 91
- Male contraception,
  - use-effectiveness of spermicidally lubricated condom, 701
  - use of hot water 60°C (rat), 549
  - use of infrared (rat), 549
  - use of microwave (rat), 549
  - use of ultrasound (rat), 549
- Male contraceptive agent, norethandrolone and testosterone, 193
- Maltase activity, seminal, effect of vasectomy, 155
- Mechanisms of action, D-norgestrel, 31
- Medroxyprogesterone acetate, three-monthly injections, 15
- Megestrol acetate, biochemical changes in Fallopian tube and uterus (monkey), 297
- Menstrual blood loss, IUD with EACA (monkey), 395
- Menstrual cycle, levels of peroxidase in cervical mucus, 677
- Metabolic effects, quinestrol-quinestanol acetate, once-a-month, 681
- Methoxyflurane, self-administered, auxiliary pain relief during suction curettage, 25
- (15S)-15 Methyl prostaglandin F<sub>2α</sub>,
  - intramuscular, termination of early gestation, 279
  - intramuscular injection, midtrimester abortion, 533
  - plasma level, vaginal ring containing 15(S) 15-methyl PGF<sub>2α</sub> methyl ester (monkey), 409
  - methyl ester, luteolytic and abortifacient effects of silicone vaginal rings (monkey), 409
- Microwave, use in male contraception (rat), 549
- Midterm abortion, induction with Silastic-PVP tubes containing prostaglandins E<sub>2</sub> and F<sub>2α</sub> (rabbit, hamster), 479
- Midtrimester abortion, intramuscular injection of 15-methyl prostaglandin F<sub>2α</sub>, 533
- Morphological studies, Daikon Shield tails, 465
- Morphology, Leydig cells, fundamental advances, 571
- Mortality Benefit Ratio, various forms of contraception, 243
- Non-returnees, evaluation of data analysis procedures, 363
- Norethandrolone (17α-ethyl-17-hydroxy-19-nor-4-androsten-3-one)
- Norethandrolone and testosterone, male contraceptive agent, 193
- Norethindrone, plasma level after I.M. injection of norethindrone enanthate, 419
- Norethindrone and ethinyl estradiol, low dose, effects on serum gonadotropins and progesterone, 329
- Norethindrone acetate, long-term contraception with steroid implants, 505
- Norethindrone enanthate (17α-ethinyl-Δ<sup>4</sup>-estrone-17β-ol-one-17β enanthate)
- Norethindrone enanthate, plasma levels of norethindrone after I.M. injection, 419
- Norethynodrel, biochemical changes in Fallopian tube and uterus (monkey), 297

## CONTRACEPTION

- D-Norgestrel, mechanisms of action, 31
- Nulligravid and nulliparous women, comparison of event rates for Dalkon Shield, 61
- Nylon suture IUCD, effect of estradiol and progesterone uptake in uterus (rat), 45
- Once-a-month contraceptive pill, quinestrol-quinestanol acetate, 681
- Oral contraceptives,
  - effect on thiamine status, 151
  - secondary amenorrhoea, treatment and follow-up, 123
- Ovulatory cycle, effect of hypophyseal stimulation by LH-RH, 271
- Oxymetholone (17 $\beta$ -hydroxy-2-(hydroxymethylene)-17-methyl-androstan-3-one)
  - Oxymetholone, abortifacient effect in early gestation, 669
- Pain relief, auxiliary, during suction curettage, 25
- Peroxidase in cervical mucus during menstrual cycle, 677
- 2-Phenyl-3-p-( $\beta$ -pyrrolidinoethoxy)-phenyl-6-methoxy benzofuran hydrochloride (DBF)
- Phosphatases, uterine, effect of postcoital stilbestrol (rabbit), 643
- Physiological status, effect of  $\alpha$ -chlorohydrin (rat), 69
- Physiology, Leydig cells, fundamental advances, 571
- Plasma levels of norethindrone after I.M. injection of norethindrone enanthate, 419
- Polyvinylpyrrolidone (PVP)
- Postcoital contraceptive agent, action of D-norgestrel, 31
- Postcoital stilbestrol, effect on uterine phosphatases (rabbit), 643
- Postpartum family planning acceptance, influence of institutional and convenience factors, 133
- Post-partum insertions, CuT-200, 289
- Post-pill amenorrhea, utilization of Lippes loop, 85
- Pregnenolone, level in endometrium, 169
- Progesterone,
  - intrauterine, effect on hypothalamic-hypophyseal-ovarian axis, 179
  - level in endometrium, 169
  - plasma, effect of intrauterine progesterone, 179
  - plasma level,
    - effect of continuous oral administration of estriol, 427
  - vaginal ring containing 15(S) 15-methyl PGF<sub>2 $\alpha$</sub>  methyl ester (monkey), 409
  - after I.M. injection of norethindrone enanthate, 419
  - serum level,
    - d-norgestrel as a postcoital contraceptive agent, 31
    - termination of early gestation with intramuscular (15S)-15 methyl prostaglandin F<sub>2 $\alpha$</sub> , 279
    - termination of early gestation with oxymetholone, 669
- Progesterone and estradiol uptake in uterus, effect of IUCD (rat), 45
- Progesterone and gonadotropins, serum levels, effect of low dose norethindrone and ethinyl estradiol, 329
- Progestogen, retro-steroid, Ro 4-8347, disposition in man, 339



- Prostaglandin, 15-methyl prostaglandin  $F_{2\alpha}$ , intramuscular midtrimester abortion, 533  
 termination of early gestation, 279
- Prostaglandin, 15(S) 15-methyl  $PGF_{2\alpha}$  methyl ester, luteolytic and abortifacient effects of silicone vaginal rings (monkey), 409
- Prostaglandin  $F_{2\alpha}$ ,  
 plasma level, vaginal ring containing 15(S) 15-methyl  $PGF_{2\alpha}$  methyl ester (monkey), 409  
 single dose with rivanol solution, extra-amniotic instillation for early second trimester abortion, 523
- Prostaglandins  $E_2$  and  $F_{2\alpha}$ , induction of midterm abortion with Silastic-PVP tubes (rabbit, hamster), 479
- Prostatic function, effect of vasectomy, 155
- Proteins, serum level, quinestrol-quinestanol acetate, once-a-month, 681
- PVP (polyvinylpyrrolidone)
- Quinestrol-quinestanol acetate, once-a-month, biochemical study, 681
- R-2323 (13-ethyl-17 $\alpha$ -ethinyl-17 hydroxygon-4,9,11-trien-3-one)
- R-2323, contraceptive effectiveness of Silastic implants, 625
- Removal of IUCD with "missing strings", use of hysteroscopy, 161
- Resorption of fetuses, effect of intrauterine copper wire (rat), 79
- Retro-steroid progestogen, Ro 4-8347, disposition in man, 339
- Rivanol solution and single prostaglandin  $F_{2\alpha}$  dose, extra-amniotic instillation for early second trimester abortion, 523
- Ro 4-8347 (6-chloro-9 $\beta$ , 10 $\alpha$ -pregna-1,4,6-triene-3,20-dione)
- Ro 4-8347, disposition in man, 339
- Safety and effectiveness of IUD, 243
- Second trimester abortion, early, extra-amniotic instillation of rivanol solution and single prostaglandin  $F_{2\alpha}$  dose, 523
- Semen profile, effect of male contraceptive agent, norethandrolone and testosterone, 193
- Sex hormone binding globulin (SHBG), influence of hormonal contraceptives, 53
- Side-effects, subjective, evaluation of contraceptive method, 363
- Silastic implants containing R-2323, contraceptive effectiveness, 625
- Silastic-PVP tubes containing prostaglandins  $E_2$  and  $F_{2\alpha}$ , induction of midterm abortion (rabbit, hamster), 479
- Sperm migration, influence of copper IUD and Lippes loop in cervical mucus, 541
- Spermatozoa, effect of  $\alpha$ -chlorohydrin (rat), 69
- Spermatozoa and luminal contents, biochemical changes in different regions of epididymis (monkey), 689
- Spermicidally lubricated condom, use-effectiveness, 701
- Stereophonic headphones, auxiliary pain relief during suction curettage, 25
- Sterilization, hysteroscopic tubal fulguration, 261
- Steroid-releasing implants, long-term contraception, norethindrone acetate, 505

## CONTRACEPTION

- Stilbestrol, postcoital, effect on uterine phosphatase (rabbit), 643
- Study population, definition, evaluation of data analysis procedures, 363
- Subcellular distribution of trace metals in normal vs. copper treated secretory endometrium, 451
- Subjects, selection, role of research design, 363
- Suction curettage, auxiliary pain relief, 25
  - use of self-administered methoxyflurane, 25
  - use of stereophonic headphones, 25
- Surface charge, blastocyst, and implantation (mouse), 441
- Sympathectomy, chemical, effect on fertility (mouse), 563
- Tails from Dalkon Shields, morphological studies, 465
- TCu-200,
  - influence on sperm migration in cervical mucus, 541
  - safety and effectiveness, 243
- Termination of early gestation, intramuscular (15S)-15 methyl prostaglandin  $F_{2\alpha}$ , 279
- Terminations, categories, evaluation of data analysis procedures, 363
- Testosterone,
  - level in endometrium, 169
  - plasma, effect of male contraceptive agent, norethandrolone and testosterone, 193
- Testosterone and norethandrolone, male contraceptive agent, 193
- Thiamine status, effect of oral contraceptives, 151
- Three-monthly injections, medroxyprogesterone acetate, 15
- Time units of observation, evaluation of data analysis procedures, 363
- Trace metals, subcellular distribution, normal vs. copper treated secretory endometrium, 451
- 3,4-Trans-2,2-dimethyl-3-phenyl-4-p-( $\beta$ -pyrrolidinoethoxy)-phenyl-7-methoxy chroman (Centchroman)
- Tubal occlusion, hysteroscopic tubal fulguration, 261
- Ultrasound, use in male contraception (rat), 549
- Unconjugated steroids in the human endometrium, 169
- Uterine phosphatases, effect of postcoital stilbestrol (rabbit), 643
- Uterus and Fallopian tube,
  - biochemical changes with progestational contraceptive steroids (monkey), 297
  - biochemical effect of Centchroman (monkey), 309
  - biochemical effect of DBF (monkey), 317
- Vaginal ring containing 15(S) 15-methyl  $PGF_{2\alpha}$  methyl ester, luteolytic and abortifacient effects (monkey), 409
- Vasectomy,
  - effect on prostatic function, 155
  - long-term endocrine responses (rat), 143

## INDEX TO VOLUME 12

## SUBJECT INDEX

- Abortion,  
     first trimester, use of intramuscular (15S) 15 methyl  
         prostaglandin  $F_{2\alpha}$ , 445  
     hypertonic saline, disappearance and concentration of  
         prostaglandin  $F_{2\alpha}$ , 679  
     second trimester, Rivanol vs. prostaglandin  $F_{2\alpha}$ , 645  
     use of antiserum to ovine luteinizing hormone $_{2\alpha}$ , 645  
         (monkey), 137  
     use of chlorpromazine and lomotil to prevent and/or  
         reduce side effects of prostaglandin  $E_2$  abortion,  
         569  
 Abortion and the Mosaic Law, 229  
 Abortion-seeking, racial differences, 199  
 17 $\alpha$ -Acetoxy-11 $\beta$ -methyl-19-nor-progesterone (SC-21009)  
 Acid-base balance, effect of norethisterone acetate + ethinyl  
     oestradiol, 395  
 Adnexal complications, following treatment with progestogen  
     implants, 629  
 $\beta$ -Adrenergic blocking agents, effect on ovulation (rabbit),  
     53  
 Alternate day administration, oral contraceptive, reduction  
     of estrogen burden, 155  
 Amniotic fluid, disappearance and concentration of prosta-  
     glandin  $F_{2\alpha}$  during hypertonic saline abortion, 679  
 Anderson-Ansell "Latex Leaf", new IUD containing copper and  
     zinc, 541  
 Antiserum to ovine luteinizing hormone, termination of  
     pregnancy (monkey), 137  
 Biochemical constituents, epididymis and vas deferens, 175  
 Blood, disappearance and concentration of prostaglandin  $F_{2\alpha}$   
     during hypertonic saline abortion, 679  
 Blood coagulation study, treatment with megestrol acetate  
     implants, 639  
 Blood gases, effect of norethisterone acetate + ethinyl  
     oestradiol, 395  
 Carcinogenicity, review of medroxyprogesterone acetate, 377  
 Cerebral cortex, metabolic action of gestagens (guinea pig),  
     221  
 Cervical contraception, use of urea as spermicidal agent,  
     465  
 Cervical dilatation, preoperative use of 15(S) 15 methyl prosta-  
     glandin  $E_2$  methyl ester, first trimester nulliparae, 59  
 Chemical occlusion with quinacrine, antagonism and reversal  
     with estrogen (monkey), 31  
 Chemical sterilization, transvaginal quinacrine plus  
     potentiating adjuvants, 11

## CONTRACEPTION

- Chemical tubal occlusion, use of intrauterine quinacrine, 95
- Chlormadinone acetate, metabolic action on cerebral cortex (guinea pig), 221
- Chlormadinone and norethindrone, complimentary, sequential antifertility effects (rabbit), 189
- $\alpha$ -Chlorohydrin, effect on motility and metabolism of ejaculated spermatozoa, 579
- Chlorpromazine and lomofil, use to prevent and/or reduce side effects of prostaglandin E, abortion, 569
- Comparative randomized study, Copper-T 200 and Dalkon Shield, 453
- Complimentary, sequential antifertility effects, chlormadinone and norethindrone (rabbit), 189
- Continuation rates, review of medroxyprogesterone acetate, 377
- Contraceptive efficacy, large doses of R2323, 211
- Copper and zinc, contained in a new Anderson-Ansell "Latex Leaf" IUD, 541
- Copper IUD,
  - influence on menstrual blood loss and iron deficiency, 317
  - reduction in eggs ovulated (rat), 327
- Copper IUDs, physiological activity, 1
- Copper-7-IUD, insertion in connection with induced abortions during first trimester, 69
- Copper-T-200 IUD, important factors in use-effectiveness, 697
- Copper-T 200 and Dalkon Shield, comparative randomized study, 453
- Cu-Ag IUD, physiological activity, 1
- Cu-Zn IUD, physiological activity, 1
- Cupric ions, effect on incorporation of thymidine and uridine into endometrial cells (rabbit), 407
- Cyproterone acetate, failure to induce sterility in male (rat), 517
- Dalkon Shield, immediate post-abortion insertion, 23
- Dalkon Shield and copper-T 200, comparative randomized study, 453
- Danazol (17 $\alpha$ -pregn-4-en-20-yno-(2,3-d) isoxazol-17-ol)
- Danazol and testosterone, changes in sperm morphology, 437
- Depo Provera, a review, 377
- Eggs ovulated, influence of a copper IUD (rat), 327
- Electrolytes, effect of norethisterone acetate + ethinyl oestradiol, 395
- Endometrium, effect of sequential oral contraceptive formulations, 655
- Epididymis and vas deferens, biochemical constituents, 175
- Estrogen, antagonism and reversal of chemical occlusion with quinacrine (monkey), 31
- Estrogen burden, oral contraceptive, reduction by alternate day administration, 155

- Estrone, methoxime derivative, antifertility activity (rat), 505
- 13-Ethyl-17-hydroxy-18,19-dinor-17 $\alpha$ -pregna-4,9,11-trien-20-yn-3-one (R2323)
- Fertility,
  - effects of immunization against lactate dehydrogenase X (mouse), 333
  - return of, review of medroxyprogesterone acetate, 377
- Fetus, effects on, review of medroxyprogesterone acetate, 377
- First trimester abortion, use of intramuscular (15S) 15 methyl prostaglandin F<sub>2</sub> $\alpha$ , 445
- First trimester nulliparae, preoperative cervical dilatation with 15(S) 15 methyl prostaglandin E<sub>2</sub> methyl ester, 59
- Galactorrhea, possible effect of IUD, 419
- Generic names for steroid hormones and related substances, guest editorial, 373
- Gestagens, metabolic action on cerebral cortex (guinea pig), 221
- Hormonal contraception, sequential formulations and endometrium, 655
- Hormonal contraceptives and plasma sex hormone binding globulin, 149
- Hypertonic saline abortion, disappearance and concentration of prostaglandin F<sub>2</sub> $\alpha$ , 679
- Immediate post-abortion, insertion,
  - copper-7-IUD, 69
  - Dalkon Shield, 23
- Immunization against lactate dehydrogenase X, effects on fertility (mouse), 333
- Implants,
  - biological effectiveness of norethindrone acetate (rat and rabbit), 549
  - megestrol acetate, study of blood coagulation, 639
  - progesterone, adnexal complications, 629
  - subdermal, clinical assessment of megestrol acetate, 615
  - subdermal, clinical assessment of norethindrone, 615
  - subdermal, clinical assessment of d-norgestrel, 615
- Infection and the IUD, 103
- Intermittent administration of noregestrel, effect on pituitary-ovarian function, 589
- Intravaginal rings,
  - containing norethindrone and norgestrel, clinical studies, 253
  - containing dl-norgestrel, serum level of d-norgestrel, 279
  - containing R2323, effect on ovarian function, 299
- Intravaginal rings for contraceptive use, editorial comment, 249
- Intravaginal rings impregnated with dl-norgestrel, plasma level of d-norgestrel, 261

## CONTRACEPTION

- Iron deficiency, influence of copper IUD, 317
- IUD,  
Anderson-Ansell "Latex Leaf" containing copper and zinc, 541  
comparative randomized study of copper-T 200 and Dalkon Shield, 453  
copper, influence on menstrual blood loss and iron deficiency, 317  
copper, physiological activity, 1  
copper, reduction in eggs ovulated (rat), 327  
copper-7, insertion in connection with induced abortions during first trimester, 69  
copper-T-200, important factors in use-effectiveness, 697  
Dalkon Shield, immediate post-abortion insertion, 23  
possible effect on galactorrhea, 419
- IUD and infection, 103
- 16-Ketoestradiol, methoxime derivative, antifertility activity (rat), 505
- Lactate dehydrogenase X, effects on fertility of immunization (mouse), 333
- Lactation,  
effect of R-2323 and appearance in milk (monkey), 665  
effects on, review of medroxyprogesterone acetate, 377
- Lomotil and chlorpromazine, use to prevent and/or reduce side effects of prostaglandin E, abortion, 569
- Low dose oral contraceptive, clinical results with norethindrone + ethinyl estradiol, 495
- Luteinizing hormone, ovine, use of antiserum in termination of pregnancy (monkey), 137
- Male contraception, reversible method of vasectomy (rabbit, rat and man), 125
- Male contraceptive,  
cyproterone acetate, failure to induce sterility (rat), 517  
danazol and testosterone, changes in sperm morphology, 437
- Medroxyprogesterone acetate, review,  
carcinogenicity, 377  
continuation rates, 377  
effects on lactation, 377  
effects on the fetus, 377  
mode of action, 377  
pregnancy rates, 377  
return of fertility, 377  
risk and benefit factors, 377  
side effects, 377
- Megestrol acetate, clinical assessment of subdermal implants, 615
- Megestrol acetate implants, study of blood coagulation, 639
- Menstrual blood loss, influence of copper IUD, 317
- Metabolic action of gestagens on cerebral cortex (guinea pig), 221

- Metabolism of ejaculated spermatozoa, effect of  $\alpha$ -chloro-  
hydrin, 579
- Metabolites of norgestrel, presence in plasma after oral  
doses of dl-, d- and l-norgestrel, 339
- Methoximes,  
antifertility activity of norethisterone-3-methoxime  
(rat), 511
- antifertility activity of derivatives of progesterone,  
estrone and 16-ketoestradiol (rat), 505
- Midtrimester abortion, use of chlorpromazine and lomotil to  
prevent and/or reduce side effects of prostaglandin  
E<sub>2</sub> abortion, 569
- Milk, appearance of R-2323 and effect on lactation (monkey),  
665
- Mode of action, review of medroxyprogesterone acetate, 377
- Mosaic Law and abortion, 229
- Motility of ejaculated spermatozoa, effect of  $\alpha$ -chlorohydrin,  
579
- Norethindrone,  
clinical assessment of subdermal implants, 615
- contained in intravaginal rings, clinical study, 253
- Norethindrone + ethinyl estradiol, clinical results with a  
new low dose, 495
- Norethindrone acetate, long-term contraception by steroid-  
releasing implants (rat and rabbit), 549
- Norethindrone and chlormadinone, complimentary, sequential  
antifertility effects (rabbit), 189
- Norethisterone, plasma levels during intramuscular norethis-  
terone oenanthate treatment, 45
- Norethisterone + mestranol vs. norethisterone + ethinyl  
estradiol, controlled clinical trial, 77
- Norethisterone acetate, progestogenic potency (Beagle), 529
- Norethisterone acetate + ethinyl oestradiol, effect on  
acid-base balance, blood gases and electrolytes,  
395
- Norethisterone enanthate, progestogenic potency (Beagle),  
529
- Norethisterone oenanthate, intramuscular, plasma levels of  
norethisterone, 45
- Norethisterone-3-methoxime, antifertility activity (rat), 511
- Norgestrel,  
contained in intravaginal rings, clinical study, 253
- effect of intermittent administration on pituitary-  
ovarian function, 589
- metabolic action on cerebral cortex (guinea pig), 221
- short-term effect on vitamin B<sub>6</sub> and B<sub>1</sub> status, 425
- Norgestrel + ethinyl estradiol, short-term effect on vitamin  
B<sub>6</sub> and B<sub>1</sub> status, 425
- d-Norgestrel,  
clinical assessment of subdermal implants, 615
- long-term contraception by steroid-releasing implants  
(rat and rabbit), 549



## CONTRACEPTION

- d-Norgestrel,
  - plasma level, after oral administration of d-norgestrel, 261
  - plasma level, when using intravaginal rings impregnated with dl-norgestrel, 261
  - progestogenic potency (Beagle), 529
  - radioimmunoassay method, 261, 279
  - serum level following intravaginal administration, 279
  - serum level following oral administration, 279
- <sup>14</sup>C-d-Norgestrel, oral dose, presence of norgestrel and metabolites in plasma, 339
- <sup>14</sup>C-dl-Norgestrel, oral dose, presence of norgestrel and metabolites in plasma, 339
- <sup>14</sup>C-l-Norgestrel, oral dose, presence of norgestrel and metabolites in plasma, 339
- dl-, d- and l-Norgestrel and their metabolites, presence in plasma, 339
- Oral administration of d-norgestrel, plasma level of d-norgestrel, 261
- Oral administration of dl-norgestrel, serum level of d-norgestrel, 279
- Oral Contraceptive,
  - clinical results with a new low dose norethindrone + ethinyl estradiol, 495
  - effect on acid-base balance, blood gases and electrolytes, 395
  - R2323, effect of weekly administration on ovarian function, 89
  - reduction of estrogen burden by alternate day administration, 155
  - sequential formulations, effect on endometrium, 655
  - two contraceptives with same gestagen and different estrogen, 77
- Oral contraceptives, effect on plasma sex hormone binding globulin levels, 149
- Ovarian function,
  - effect of intermittent norgestrel administration, 589
  - effect of R2323 released from vaginal rings, 299
  - effect of weekly administration of oral R2323, 89
- Ovarian steroids and pituitary gonadotropins, plasma profile during SC-21009 administration, 37
- Ovulation, effect of  $\beta$ -adrenergic blocking agents (rabbit), 53
- Physiological activity, IUDs containing copper, 1
- Physiology of epididymis and vas deferens, biochemical constituents, 175
- Pituitary gonadotropins and ovarian steroids, plasma profile during SC-21009 administration, 37
- Pituitary-ovarian function, effect of intermittent norgestrel administration, 589
- Postpartum treatment with R-2323, appearance in milk and effects on lactation (monkey), 665



- 17 $\alpha$ -Pregn-4-en-20-yno-(2,3-d) isoxazol-17-ol (Danazol)  
 Pregnancy rates, review of medroxyprogesterone acetate, 377  
 Progesterone,  
     methoxime derivative, antifertility activity (rat, 505  
     progestogenic potency (Beagle), 529  
 Progestin only fertility control, sequential chlormadinone  
     and norethindrone (rabbit), 189  
 Progestogen implants, adnexal complications, 629  
 Progestogenic potencies of progestogens (Beagle), 529  
 Prostaglandin, (15S) 15 methyl PGF<sub>2 $\alpha$</sub> , intramuscular, use in  
     first trimester abortion, 445  
 Prostaglandin E<sub>2</sub>, 15(S) 15 methyl PGE<sub>2</sub> methyl ester, use in  
     preoperative cervical dilatation, first trimester  
     nulliparae, 59  
 Prostaglandin E<sub>2</sub> abortion, use of chlorpromazine and lomotil  
     to prevent and/or reduce side effects, 569  
 Prostaglandin F<sub>2 $\alpha$</sub> , disappearance and concentration during  
     hypertonic saline abortion, 679  
 Prostaglandin F<sub>2 $\alpha$</sub>  vs. Rivanol, induction of second trimester  
     abortion, 645  
 Quinacrine,  
     chemical occlusion, antagonism and reversal with estrogen  
     (monkey), 31  
     use in chemically induced tubal occlusion, 95  
 Quinacrine plus potentiating adjuvants, transvaginal chemical  
     sterilization, 11  
 R2323 (13-ethyl-17-hydroxy-18,19-dinor-17 $\alpha$ -pregna-4,9,11-  
     trien-20-yn-3-one)  
 R2323,  
     appearance in milk and effects on lactation (monkey),  
         665  
     effect when released from vaginal rings on ovarian  
         function, 299  
     given after a missed period, lack of contraceptive  
         efficacy, 211  
     given before implantation, lack of contraceptive  
         efficacy, 211  
     lack of contraceptive efficacy of large doses, 211  
     oral, effect of weekly administration on ovarian  
         function, 89  
     plasma concentration from vaginal rings, 309  
     radioimmunoassay method, 309  
 Racial differences in abortion-seeking, 199  
 Radioimmunoassay method for measuring d-norgestrel, 261, 279  
 Radioimmunoassay method for measuring R2323, 309  
 Reversible method of vasectomy (rabbit, rat and man), 125  
 Risk and benefit factors, review of medroxyprogesterone  
     acetate, 377  
 Rivanol vs. prostaglandin F<sub>2 $\alpha$</sub> , induction of second trimester  
     abortion, 645  
 15(S) 15 methyl prostaglandin E<sub>2</sub> methyl ester, use in pre-  
     operative cervical dilatation, first trimester  
     nulliparae, 59

## CONTRACEPTION

- (15S) 15 methyl prostaglandin  $F_{2\alpha}$ , intramuscular, use in first trimester abortion, 445
- SC-21009 (17 $\alpha$ -acetoxy-11 $\beta$ -methyl-19-nor-progesterone)
- SC-21009, plasma profile of pituitary gonadotropins and ovarian steroids during administration, 37
- Second trimester abortion, Rivanol vs. prostaglandin  $F_{2\alpha}$ , 645
- Sequential formulations of oral contraceptive, effect on endometrium, 655
- Sex hormone binding globulin, effect of hormonal contraceptives, 149
- Side effects, review of medroxyprogesterone acetate, 377
- Sperm morphology, changes with danazol and testosterone, 437
- Spermatozoa, effect of  $\alpha$ -chlorohydrin on motility and metabolism, 579
- Spermicidal agent, urea as a cervical contraceptive, 465
- Sterility, male, failure to induce with cyproterone acetate (rat), 517
- Sterilization, chemical,
  - transvaginal quinacrine plus potentiating adjuvants, 11
  - use of quinacrine, 95
- Sterilization, chemical occlusion with quinacrine, antagonism and reversal with estrogen (monkey), 31
- Steroid hormones and related substances, use of generic names, guest editorial, 373
- Steroid methoximes,
  - antifertility activity of norethisterone-3-methoxime (rat), 511
  - antifertility activity of progesterone, estrone and 16-ketoestradiol derivatives (rat), 505
- Termination of pregnancy using antiserum to ovine luteinizing hormone (monkey), 137
- Thymidine and uridine, effect of cupric ions on incorporation into endometrial cells (rabbit), 407
- Transvaginal chemical sterilization, quinacrine plus potentiating adjuvants, 11
- Urea, use as a spermicidal agent in cervical contraception, 465
- Uridine and thymidine, effect of cupric ions on incorporation into endometrial cells (rabbit), 407
- Use-effectiveness, important factors for copper-T-200 IUD, 697
- Vaginal rings, containing R2323,
  - effect on ovarian function, 299
  - plasma concentration of R2323, 309
- Vas deferens and epididymis, biochemical constituents, 175
- Vasectomy, reversible method (rabbit, rat and man), 125
- Vitamin B<sub>6</sub> and B<sub>1</sub> status,
  - short-term effect of norgestrel, 425
  - short-term effect of norgestrel + ethinyl estradiol, 425
- Zinc and copper, contained in a new Anderson-Ansell "Latex Leaf" IUD, 541

